Evidence map›Paper›PMID 32564353›Full record

ArticleMedical physics2020

Fraction-variant beam orientation optimization for intensity-modulated proton therapy.

Wenbo Gu, Daniel O'Connor, Dan Ruan, Wei Zou, Lei Dong, Ke Sheng

Open access · greenAbstract read
In one paragraph

Article in Medical physics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Wenbo GuDepartment of Radiation Oncology, University of California-Los Angeles, Los Angeles, CA, 90095, USA.
Daniel O'ConnorDepartment of Radiation Oncology, University of California-Los Angeles, Los Angeles, CA, 90095, USA.
Dan RuanDepartment of Radiation Oncology, University of California-Los Angeles, Los Angeles, CA, 90095, USA.
Wei ZouDepartment of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Lei DongDepartment of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Ke ShengDepartment of Radiation Oncology, University of California-Los Angeles, Los Angeles, CA, 90095, USA.
University of California, Los Angeles · USUniversity of Pennsylvania · US

Funding

Development of a versatile robotic radiation therapy systemR44CA183390 · NCI · RADIABEAM TECHNOLOGIES, LLC · PI SHENG, KE, YONEMOTO, JAY · 2017 to 2024
$5.8M
Robust IMPT with automated beam orientation and scanning spot optimizationR01CA230278 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SHENG, KE · 2019 to 2023
$1.9M
Motion Management of Pancreatic Cancer in MRI-Guided RadiotherapyR01CA188300 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SHENG, KE · 2015 to 2019
$1.7M
(NCI) Developing an Intermediate Energy Linac for Robotic RadiotherapyR43CA183390 · NCI · RADIABEAM TECHNOLOGIES, LLC · PI BOUCHER, SALIME · 2015 to 2016
$265k
NCI NIH HHS R01 CA188300NCI NIH HHS R01 CA230278NCI NIH HHS R43 CA183390NCI NIH HHS R44 CA183390NIH HHS R01CA188300NIH HHS R01CA230278NIH HHS R43CA183390NIH HHS R44CA183390
6 · The paper itself

Abstract

purposeTo achieve a superior balance between dosimetry and the delivery efficiency of intensity-modulated proton therapy (IMPT) using as few beams as possible in a single fraction, we optimally vary beams in different fractions.

methodsIn the optimization, 400~800 feasible noncoplanar beams were included in the candidate pool. For each beam, the doses of all scanning spots covering the target volume and a margin were calculated. The fraction-variant beam orientation optimization (FVBOO) problem was formulated to include three terms: two quadratic dose fidelity terms to penalize the deviation of planning target volume fractional dose and organs at risk (OAR) cumulative doses from prescription, respectively; an L2,1/2-norm group sparsity term to control the number of active beams per fraction to between 1 and 4. The Fast Iterative Shrinkage-Thresholding Algorithm (FISTA) was applied to solve this problem. FVBOO was tested on a patient with base-of-skull (BOS) tumor of 5 fractions (5f) and 30 fractions (30f) with an average number of active beams per fraction varying between 4 and 1. In addition, one bilateral head-and-neck (H&N) patient, and one esophageal cancer (ESG) patient of 30f were tested with about three active beams per fraction. The results were compared with IMPT plans that use fixed beams in each fraction. The fixed beams were selected using the group sparsity term with a fraction-invariant BOO (FIBOO) constraint.

resultsVarying beams were chosen in either the 5f or 30f FVBOO plans. While similar number of beams per fraction was selected as the FIBOO plan, the FVBOO plans were able to spare the OARs better, with an average reduction of [Dmean, Dmax] from the FIBOO plans by [0.85, 2.08] Relative Biological Effective Gy (GyRBE) in the 5f plan and [1.87, 4.06] GyRBE in the 30f plans. While reducing the number of beams per fraction in the BOS patient, a three-beam/fraction 5f FVBOO plan performs comparably as the four-beam FIBOO plan and a two-beam/fraction 30f FVBOO plan still provides superior dosimetry.

conclusionFraction-variant beam orientation optimization allows the utilization of a larger beam solution space for superior dose distribution in IMPT while maintaining a practical number of beams in each fraction.

Indexed as

Proton TherapyRadiotherapy, Intensity-ModulatedAlgorithmsHumansOrgans at RiskRadiotherapy DosageRadiotherapy Planning, Computer-Assistedfraction variantintensity modulated proton therapyoptimization

Identifiers

PMID32564353
PMCPMC7845556
OpenAlexW3036297661

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.